✓ Translated by DotMD AI Clinical Council Source: Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association • Randomized Controlled Trial

Verify Primary Source: NIH PubMed PMID #25502581 ↗

Randomized Controlled Trial: Losartan reduces insulin resistance by inhibiting oxidative stress and enhancing insulin signaling transduction (N = 65)

Original Paper Title: “Losartan reduces insulin resistance by inhibiting oxidative stress and enhancing insulin signaling transduction”

Elena Rostova (AI Quant) Rigor Score

82 / 100

Sample Size (Participants)

N = 65

Evidence Classification

Randomized Controlled Trial

Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways

These results suggest that the effect of losartan on insulin resistance is associated with the reduction of oxidative stress and inflammation in patients with type 2 DKD as well as the activation of insulin signal pathway in insulin-resistance 3T3-L1 adipocytes through modulation of PI3K pathway. (Clinical Trials.
Study Design & Sample: Randomized Controlled Trial published in Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association (N = 65 human participants).
Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association (2015), this randomized controlled trial evaluating 65 human participants investigated: Inhibition of the rennin-angiotensin system (RAS) could reduce insulin resistance in patients with hypertension and diabetic kidney disease (DKD), but whether the effect of losartan on insulin resistance is associated with reduction of oxidative stress and enhancement of insulin signaling transduction has not been fully elucidated. Key clinical takeaway: These results suggest that the effect of losartan on insulin resistance is...

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2015-03-15; N = 65; Rigor 82/100): These results suggest that the effect of losartan on insulin resistance is associated with the reduction of oxidative stress and inflammation in patients with type 2 DKD as well as the activation of insulin signal pathway in insulin-resistance 3T3-L1 adipocytes through modulation of PI3K pathway. (Clinical Trials.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Randomized Controlled Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: losartan-potassium → Rx: losartan-potassium-and-hydrochlorothiazide → Rx: insulin-aspart → Rx: insulin-aspart-szjj → Condition: diabetes-in-children-and-teens → Condition: diabetes-complications →

Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 25502581: Randomized Controlled Trial: Losartan reduces insulin resistance by inhibiting oxidative stress and enhancing insulin signaling transduction (N = 65)

3 of 3 Free Questions Remaining